Porton Fine Chemicals Ltd (300363) - Total Assets
Based on the latest financial reports, Porton Fine Chemicals Ltd (300363) holds total assets worth CN¥8.58 Billion CNY (≈ $1.26 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Porton Fine Chemicals Ltd - Total Assets Trend (2009–2024)
This chart illustrates how Porton Fine Chemicals Ltd's total assets have evolved over time, based on quarterly financial data. Also see market value of Porton Fine Chemicals Ltd for the company's overall valuation and market capitalisation.
Porton Fine Chemicals Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Porton Fine Chemicals Ltd's total assets of CN¥8.58 Billion consist of 36.8% current assets and 63.2% non-current assets. Review debt load of Porton Fine Chemicals Ltd to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.7% |
| Accounts Receivable | CN¥865.90 Million | 9.8% |
| Inventory | CN¥771.31 Million | 8.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥258.75 Million | 2.9% |
| Goodwill | CN¥292.91 Million | 3.3% |
Asset Composition Trend (2009–2024)
This chart illustrates how Porton Fine Chemicals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Porton Fine Chemicals Ltd (300363) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Porton Fine Chemicals Ltd's current assets represent 36.8% of total assets in 2024, a decrease from 43.1% in 2009.
- Cash Position: Cash and equivalents constituted 16.7% of total assets in 2024, down from 17.5% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 6.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 9.8% of total assets.
Porton Fine Chemicals Ltd Competitors by Total Assets
Key competitors of Porton Fine Chemicals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601
|
China | CN¥13.93 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
|
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201
|
China | CN¥2.35 Billion |
Porton Fine Chemicals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.87 | 2.12 | 2.22 |
| Quick Ratio | 1.46 | 1.59 | 1.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.46 Billion | CN¥1.70 Billion | CN¥1.20 Billion |
Porton Fine Chemicals Ltd - Advanced Valuation Insights
This section examines the relationship between Porton Fine Chemicals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.16 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -6.1% |
| Total Assets | CN¥8.82 Billion |
| Market Capitalization | $1.90 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Porton Fine Chemicals Ltd's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Porton Fine Chemicals Ltd's assets decreased by 6.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Porton Fine Chemicals Ltd (2009–2024)
The table below shows the annual total assets of Porton Fine Chemicals Ltd from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.82 Billion ≈ $1.29 Billion |
-6.05% |
| 2023-12-31 | CN¥9.38 Billion ≈ $1.37 Billion |
-7.49% |
| 2022-12-31 | CN¥10.14 Billion ≈ $1.48 Billion |
+54.59% |
| 2021-12-31 | CN¥6.56 Billion ≈ $960.23 Million |
+45.92% |
| 2020-12-31 | CN¥4.50 Billion ≈ $658.04 Million |
+13.69% |
| 2019-12-31 | CN¥3.96 Billion ≈ $578.81 Million |
-9.58% |
| 2018-12-31 | CN¥4.37 Billion ≈ $640.12 Million |
+53.59% |
| 2017-12-31 | CN¥2.85 Billion ≈ $416.76 Million |
-0.81% |
| 2016-12-31 | CN¥2.87 Billion ≈ $420.18 Million |
+20.68% |
| 2015-12-31 | CN¥2.38 Billion ≈ $348.18 Million |
+28.27% |
| 2014-12-31 | CN¥1.85 Billion ≈ $271.44 Million |
+95.65% |
| 2013-12-31 | CN¥948.09 Million ≈ $138.74 Million |
+19.85% |
| 2012-12-31 | CN¥791.08 Million ≈ $115.76 Million |
+37.74% |
| 2011-12-31 | CN¥574.32 Million ≈ $84.04 Million |
+24.74% |
| 2010-12-31 | CN¥460.41 Million ≈ $67.37 Million |
+51.18% |
| 2009-12-31 | CN¥304.55 Million ≈ $44.57 Million |
-- |
About Porton Fine Chemicals Ltd
Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, produc… Read more